N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
Phase 2 N=192 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
Influenza
Primary: Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
Phase 4 N=371 Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
HIV Infection · Hepatitis B
Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=106 Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
Risk Behavior · Medication Adherence · HIV
Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants
N/A N=37 Cardiovascular Prevention for Persons With HIV
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
Phase 2 N=128 Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women
HIV Infections · H1N1 Influenza Virus
Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
N/A N=100 Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms
HIV (Human Immunodeficiency Virus) · AIDS (Acquired Immunodeficiency Syndrome)
Primary: Symptom Burden Score — 1.08; 1.06; 0.83; 0.71 score on a scale — p=0.02
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Phase 2 N=123 Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Herpes Zoster
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 6; 2 Participants
N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
Phase 4 N=546 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants
Phase 2 N=36 HIV and Fat Accumulation
HIV Infection
Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
N/A N=8,202 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
HIV · AIDS
Primary: Incidence Rate of Malignancies — 0.30; 0.27; 0.02; 0.62 malignancies per 100 person-years
N/A N=7 Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
HIV Infections
Primary: Rate of Medication Adherence — 2; 1 Participants
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Phase 2 N=395 Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Herpes Zoster · HIV Infections
Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…
Phase 2 N=149 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 2 N=252 A Safety and Immune Response Study of 2 Experimental HIV Vaccines
HIV Infection
Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen — 42; 26; 126; 16 Participants
N/A N=18 The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Men
Human Immunodeficiency Virus · Cardiometabolic Risk
Primary: Number of Eligible Participants Refusing to Participate. — 0 Participants
Phase 1 N=65 A Safety and Immunogenicity Trial of IHV01
HIV Infection
Primary: Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms — 3; 8; 4; 5 Participants